Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology
Open Access
- 19 May 2021
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 7 (1), 035-042
- https://doi.org/10.17352/2581-5407.000040
Abstract
In the setting of upfront chemotherapy, some degree of reduction in primary tumor volume may occur.Keywords
This publication has 69 references indexed in Scilit:
- The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysisJournal of the American Academy of Dermatology, 2013
- Immune modulation of the tumor microenvironment for enhancing cancer immunotherapyOncoImmunology, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical SignificanceCancer Microenvironment, 2012
- The determinants of tumour immunogenicityNature Reviews Cancer, 2012
- Immunotherapy earns its spot in the ranks of cancer therapyThe Journal of Experimental Medicine, 2012
- Granzyme B-induced apoptosis in cancer cells and its regulation (Review)International Journal of Oncology, 2010
- Immune Regulation of CancerJournal of Clinical Oncology, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesThe Journal of Experimental Medicine, 2009